Timo Reislander

Munich, BY 80687, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Unresectable biliary tract cancer: Current and future systemic therapy.

Unresectable biliary tract cancer: Current and future systemic therapy.

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 05, 2024

Sustained Clinical Response to Ivosidenib in Previously Treated Patients with Advanced Intrahepatic Cholangiocarcinoma Harboring an IDH1 R132 Mutation: Two Case Reports.

Sustained Clinical Response to Ivosidenib in Previously Treated Patients with Advanced Intrahepatic Cholangiocarcinoma Harboring an IDH1 R132 Mutation: Two Case Reports.

Journal: Case reports in oncology

Published: February 02, 2024

Subgroup analyses from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: results of the TALLISUR trial.

Subgroup analyses from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: results of the TALLISUR trial.

Journal: BMC cancer

Published: September 06, 2023

Long-Term Progression-Free Survival of a Pre-Treated Patient with Metastatic Colorectal Cancer Receiving Trifluridine/Tipiracil.

Long-Term Progression-Free Survival of a Pre-Treated Patient with Metastatic Colorectal Cancer Receiving Trifluridine/Tipiracil.

Journal: Chemotherapy

Published: March 13, 2023

Effectiveness, safety and quality of life of trifluridine/tipiracil in pretreated patients with metastatic colorectal cancer: Real-world data from the noninterventional TACTIC study in Germany.

Effectiveness, safety and quality of life of trifluridine/tipiracil in pretreated patients with metastatic colorectal cancer: Real-world data from the noninterventional TACTIC study in Germany.

Journal: International journal of cancer

Published: November 25, 2022

Efficacy, safety and quality-of-life data from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: results of the TALLISUR trial.

Efficacy, safety and quality-of-life data from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: results of the TALLISUR trial.

Journal: ESMO open

Published: September 27, 2021

DNA Damage and Cancer Immunotherapy: A STING in the Tale.

DNA Damage and Cancer Immunotherapy: A STING in the Tale.

Journal: Molecular cell

Published: May 27, 2020

BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors.

BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors.

Journal: Nature communications

Published: December 06, 2018

Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance.

Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance.

Journal: EMBO molecular medicine

Published: October 26, 2018

A novel three-dimensional heterotypic spheroid model for the assessment of the activity of cancer immunotherapy agents.

A novel three-dimensional heterotypic spheroid model for the assessment of the activity of cancer immunotherapy agents.

Journal: Cancer immunology, immunotherapy : CII

Published: October 16, 2015

Showing 1-10 of 10

Last Updated: 09/26/2026